FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912976929> ?p ?o ?g. }

• W2912976929 endingPage "3528" @default.
• W2912976929 startingPage "3528" @default.
• W2912976929 abstract "Abstract Disease severity and healthcare utilization varies widely among persons with sickle cell disease (SCD). Hydroxyurea (HU) has been demonstrated to reduce rates of pain and acute chest syndrome, the leading causes of inpatient utilization in patients with Hb SS and S β°-thalassemia in clinical trials. We recently reported that HU was clinically effective in reducing rates of pain and acute chest syndrome in patients who initiate treatment. Use of hydroxyurea in SS/S β°-thalassemia has increased markedly since 2010. Thus we sought to detemine trends of hospital utilization for acute illness during an 8 yr in which HU utilization increased markedly (2010-2017). Data from years 2010-201 were obtained from the SCD database and patient records at Children's Healthcare of Atlanta (CHOA). Utilization data were restricted to acute care admissions. Admissions for elective procedures, non-SCD related discharge diagnoses, rare SCD genotypes, and patients who had undergone bone marrow transplant were excluded. Patients were compared based on number of hospitalizations, age, sex, SCD genotype (SS/S β°-thalassemia vs Hb SC/S β+thalassemia), and discharge diagnosis. A total of 3,116 patients had at least one encounter between 2010 and 2017; 2,947 patients met inclusion criteria. From 2010-2017 the total number of active patients per year increased from 1,546 patients to 1,789 patients (+16%), while the total number acute care admissions increased from 1,295 admissions to 1,609 admissions (+24%). There were no significant differences in the proportion of patients with genotypes SS/S β° thalassemia genotypes (67.0% vs 63.9%, p=0.06). Overall patients with SS/S β° thalassemia had higher admission rates compared to SC/S β+ thalassemia patients (0.94 vs 0.57 admissions per patient per year). During the study period. overall admission rates in SCD (acute illness hospitalizations/patient/yr) increased from a low of 0.74 in 2011 to a high of 0.90 in 2017. The proportion of admissions attributed to SS/S β°-thalassemia patients decreased (79.2% in 2010 vs 72.3% in 2017, p<0.0001). However, admission rate in SC/S β+ thalassemia increased (0.53 to 0.69 admissions per patient per year). Overall, over 60% of patients were not admitted in any given year, and the proportion of patients with 0-1 admissions in a given year remained unchanged. However, the proportion of super high hospital utilizers (SHHU), patients with 8 or more admissions in a given year, increased by 185%. In 2001 this group made up 0.6% of all patients and accounted for 7.3% of admissions; in 2017 SHHU had increased 1.8% of patients and 24.3% of admissions. There was no difference in genotype or sex between SHHU and non-SHHU patients. SHHU were older (>90% of patients over age 8 years), and had greater percentages of admissions for pain and acute chest syndrome then non-SHHU. In conclusion, during a period in which HU utilization in SS/S β°-thalassemia increased significantly, hospital utilization for acute illness in SS/S β° thalassemia decreased as expected. However, during the same period there was an unexpected increase in overall hospital utilization for acute illness in SCD. This increase in hospital utilization was the result of 1) a marked increase in SHHU and 2) an overall increased utilization in SC/S β+ thalassemia. Disclosures Dampier: Pfizer: Research Funding." @default.
• W2912976929 created "2019-02-21" @default.
• W2912976929 creator A5011497057 @default.
• W2912976929 creator A5049234597 @default.
• W2912976929 creator A5058205892 @default.
• W2912976929 creator A5063557553 @default.
• W2912976929 creator A5064394866 @default.
• W2912976929 creator A5081343618 @default.
• W2912976929 date "2018-11-29" @default.
• W2912976929 modified "2023-09-27" @default.
• W2912976929 title "Trends in Hospital Utilization for Acute Illness in a Large Population-Based Cohort of Children and Adolescents with Sickle Cell Disease (SCD): 2010–2017" @default.
• W2912976929 doi "https://doi.org/10.1182/blood-2018-99-120067" @default.
• W2912976929 hasPublicationYear "2018" @default.
• W2912976929 type Work @default.
• W2912976929 sameAs 2912976929 @default.
• W2912976929 citedByCount "0" @default.
• W2912976929 crossrefType "journal-article" @default.
• W2912976929 hasAuthorship W2912976929A5011497057 @default.
• W2912976929 hasAuthorship W2912976929A5049234597 @default.
• W2912976929 hasAuthorship W2912976929A5058205892 @default.
• W2912976929 hasAuthorship W2912976929A5063557553 @default.
• W2912976929 hasAuthorship W2912976929A5064394866 @default.
• W2912976929 hasAuthorship W2912976929A5081343618 @default.
• W2912976929 hasBestOaLocation W29129769291 @default.
• W2912976929 hasConcept C126322002 @default.
• W2912976929 hasConcept C160735492 @default.
• W2912976929 hasConcept C162324750 @default.
• W2912976929 hasConcept C187212893 @default.
• W2912976929 hasConcept C2777799968 @default.
• W2912976929 hasConcept C2778620579 @default.
• W2912976929 hasConcept C2779134260 @default.
• W2912976929 hasConcept C2780976302 @default.
• W2912976929 hasConcept C2781385661 @default.
• W2912976929 hasConcept C2908647359 @default.
• W2912976929 hasConcept C50522688 @default.
• W2912976929 hasConcept C71924100 @default.
• W2912976929 hasConcept C72563966 @default.
• W2912976929 hasConcept C99454951 @default.
• W2912976929 hasConceptScore W2912976929C126322002 @default.
• W2912976929 hasConceptScore W2912976929C160735492 @default.
• W2912976929 hasConceptScore W2912976929C162324750 @default.
• W2912976929 hasConceptScore W2912976929C187212893 @default.
• W2912976929 hasConceptScore W2912976929C2777799968 @default.
• W2912976929 hasConceptScore W2912976929C2778620579 @default.
• W2912976929 hasConceptScore W2912976929C2779134260 @default.
• W2912976929 hasConceptScore W2912976929C2780976302 @default.
• W2912976929 hasConceptScore W2912976929C2781385661 @default.
• W2912976929 hasConceptScore W2912976929C2908647359 @default.
• W2912976929 hasConceptScore W2912976929C50522688 @default.
• W2912976929 hasConceptScore W2912976929C71924100 @default.
• W2912976929 hasConceptScore W2912976929C72563966 @default.
• W2912976929 hasConceptScore W2912976929C99454951 @default.
• W2912976929 hasIssue "Supplement 1" @default.
• W2912976929 hasLocation W29129769291 @default.
• W2912976929 hasOpenAccess W2912976929 @default.
• W2912976929 hasPrimaryLocation W29129769291 @default.
• W2912976929 hasRelatedWork W2141187979 @default.
• W2912976929 hasRelatedWork W2171352201 @default.
• W2912976929 hasRelatedWork W2188367746 @default.
• W2912976929 hasRelatedWork W242090125 @default.
• W2912976929 hasRelatedWork W2581790269 @default.
• W2912976929 hasRelatedWork W4206878687 @default.
• W2912976929 hasRelatedWork W4232862935 @default.
• W2912976929 hasRelatedWork W4292341608 @default.
• W2912976929 hasRelatedWork W4313579122 @default.
• W2912976929 hasRelatedWork W4221155949 @default.
• W2912976929 hasVolume "132" @default.
• W2912976929 isParatext "false" @default.
• W2912976929 isRetracted "false" @default.
• W2912976929 magId "2912976929" @default.
• W2912976929 workType "article" @default.